Holen Sie sich die Stockscreener-App
0.68
1.49%
0.01
Schlusskurs vom Vortag:
$0.67
Offen:
$0.6998
24-Stunden-Volumen:
107.73K
Relative Volume:
0.30
Marktkapitalisierung:
$4.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-5.85M
KGV:
-0.1017
EPS:
-6.6877
Netto-Cashflow:
$-8.00M
1W Leistung:
+2.72%
1M Leistung:
-30.80%
6M Leistung:
-58.54%
1J Leistung:
-90.63%
1-Tages-Spanne:
$0.6594
$0.7199
1-Wochen-Bereich:
$0.627
$0.7199
52-Wochen-Spanne:
$0.627
$15.06
Alzamend Neuro Inc Stock (ALZN) Company Profile
Firmenname
Alzamend Neuro Inc
Sektor
Branche
Telefon
844-722-6333
Adresse
3500 LENOX RD. NE, ATLANTA
Vergleichen Sie ALZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
0.68 | 4.37M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-01 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
Geode Capital Management LLC Buys New Stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) - Defense World
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital - Seeking Alpha
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 37.6% in April - Defense World
Form 8-KCurrent report - ADVFN
ALZN Stock Sees Decline of Approximately -12.99% in Last Five Days - knoxdaily.com
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey
Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com Australia
Alzamend neuro director William Horne buys $3,285 in common stock - Investing.com India
Alzamend Neuro director Milton Ault buys $2,968 in company stock - Investing.com India
Alzamend Neuro director Milton Ault buys $2,968 in company stock By Investing.com - Investing.com South Africa
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital - The Manila Times
Major Breakthrough: New Alzheimer's Drug Advances to Phase II at Top Hospital - Stock Titan
Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock By Investing.com - Investing.com Australia
Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock - Investing.com
Alzamend Neuro director William B. Horne purchases $4,891 in shares - Investing.com India
Alzamend Neuro director William B. Horne purchases $4,891 in shares By Investing.com - Investing.com UK
Alzamend Neuro director William B. Horne buys $4,851 in stock - Investing.com India
Alzamend Neuro director William B. Horne buys $4,851 in stock By Investing.com - Investing.com South Africa
Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com Australia
Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares By Investing.com - Investing.com South Africa
Alzamend Neuro, Inc. Plans Phase II Clinical Study of AL001 in Major Depressive Disorder to Compare Lithium Delivery with Marketed Products - Nasdaq
Alzamend Neuro Announces Initiation Date of Phase II - GlobeNewswire
Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital - StockTitan
Alzamend Neuro (ALZN) Projected to Post Earnings on Monday - Defense World
Alzamend Neuro director Milton Ault buys $68 in stock By Investing.com - Investing.com Australia
Alzamend Neuro director Milton Ault buys $68 in stock - Investing.com
Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 332.2% - Defense World
Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline - Investing.com Australia
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - BioSpace
Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline By Investing.com - Investing.com South Africa
Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025 - Marketscreener.com
Major PTSD Breakthrough: New Lithium Treatment Heads to Phase II Trial at Top Hospital - StockTitan
EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits - Benzinga
Alzamend Neuro Inc. (ALZN) reports earnings - Quartz
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 33.0% in February - Defense World
Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment Of Bipolar Disorder To Take Place At Massachusetts General Hospital - Marketscreener.com
Alzamend Neuro announces initiation date of Phase II trial of AL001 - TipRanks
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital - The Manila Times
Alzamend Neuro Announces Phase II Clinical Study of AL001 for Bipolar Disorder Expected to Start in Q3 2025 - Nasdaq
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):